Novo Nordisk develops new mechanical insulin pill with star researchers from MIT

Novo Nordisk has developed a new pill technology, the future basis for an insulin pill, in collaboration with star researcher Robert Langer and his team at MIT. The company expects clinical studies to take place in two to three years.

The new pill technology Lumi consists of a three-pointed needle construction, that is shot into the small intestine by a spring and injects insuline into the intestine wall. | Photo: MIT/ PR

It was to the “deep frustration” of research director Mads Krogsgaard Thomsen that Novo Nordisk gave up on a year long project to develop an insulin pill, that would have given type 1 diabetics a needle-free alternative, in 2016.

The pill had been predicted to have a future as one of the world’s best-selling medicines, with potential sales of up to USD 10 billion a year, if Novo Nordisk could develop it to be market-ready.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs